NYSE · Drug Manufacturers - General · USD

Organon & Co. (OGN) Stock Analysis

Organon & Co. (OGN) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.

OGN

$13.78

+$0.01 (+0.07%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OGN with… →

OGN Key Statistics

As of Sep 4, 2026

Trading

Open: $13.76
Previous Close: $13.77
Day's Range: 13.76–13.78
52-Week Range: 5.69–13.79
Volume: 4.87M
Beta: 1.52

Valuation

Market Cap: $3.62B
P/E Ratio: 17.67
Forward P/E: 3.81
P/S ratio: 0.59
EPS (ttm): 0.78

Financials (FY)

Revenue (FY): $6.22B−2.92%
Net Income (FY): $187.00M−78.36%
Profit margin: 3.41%
Shares Outstanding: 262.61M
1-Year Return: +43.31%

Dividend and dates

Dividend: $0.08+0.58%
Ex-Dividend Date: August 14, 2026
Earnings Date: November 9, 2026estimated
Avg Volume: 2.72M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−6.84%−4.86%−45.12%+9.92%−50.71%+92.95%

2021*20222023202420252026*

Year	Return
2026 (partial year)	+92.95%
2025	−50.71%
2024	+9.92%
2023	−45.12%
2022	−4.86%
2021 (partial year)	−6.84%

As of September 4, 2026.

OGN Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$6.22B	$187.00M	3.0%
2024	$6.40B	$864.00M	13.5%
2023	$6.26B	$1.02B	16.3%
2022	$6.17B	$917.00M	14.9%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$6.22B	$3.31B	$1.23B	$187.00M	3.0%
2024	$6.40B	$3.72B	$1.49B	$864.00M	13.5%
2023	$6.26B	$3.75B	$1.33B	$1.02B	16.3%
2022	$6.17B	$3.88B	$1.71B	$917.00M	14.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OGN Dividend History

’21’22’23’24’25’26*

$0.34−69.6% vs 2024

Dividends per share, 2025 · 4 payments

Year	Dividends per share	Payments	Change
2026*	$0.06	3	—
2025	$0.34	4	−69.6%
2024	$1.12	4	+0.0%
2023	$1.12	4	+0.0%

Year	Dividends per share	Payments	Change
2026 (partial year)	$0.06	3	—
2025	$0.34	4	−69.6%
2024	$1.12	4	+0.0%
2023	$1.12	4	+0.0%
2022	$1.12	4	+100.0%
2021	$0.56	2	—

Most recent payment: $0.02 per share, ex-dividend August 14, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

OGN Valuation vs Drug Manufacturers - General Median

Median of 21 stocks

Metric	OGN	Drug Manufacturers - General median	vs median
P/E	17.67	24.69	28% below
P/S ratio	0.59	3.13	0.2x the median
Profit margin	3.41%	8.09%	4.7 pts below

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Organon & Co. (OGN) at $3.62B. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. Headcount on file is 10,000.

The most recent close on file for OGN is $13.78, dated September 4, 2026. That is +$0.01 (+0.07%) against the previous close. The 52-week range on file runs from $5.69 to $13.79. The latest close sits 142.18% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $6.22B. Against the prior fiscal year total of $6.40B, that is a change of −2.92%. The same year closed with net income of $187.00M. That is −78.36% against the prior fiscal year. Profit margin runs at 3.41%. That is 4.7 percentage points below the Drug Manufacturers - General median of 8.09%. Earnings per share on a trailing basis come to 0.78.

Across the 4 fiscal years on file, revenue moves from $6.17B in 2022 to $6.22B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 17.67. That is 28.43% below the Drug Manufacturers - General median of 24.69. The forward P/E on file is 3.81. The price-to-sales ratio is 0.59. On price-to-sales that is 0.2 times the Drug Manufacturers - General median of 3.13. 21 Drug Manufacturers - General companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +43.31%. Measured over 5 years, that is −13.98% a year compounded. The reported beta is 1.52. Daily returns over the trailing 5 years annualize to a volatility of 47.5%.

Growth & Income

Shareholders receive a dividend, yielding 0.58% on the latest price. That is 2.1 percentage points below the Drug Manufacturers - General median yield of 2.7%. At the indicated rate that is $0.08 a share a year. The ex-dividend date on file is August 14, 2026. Dividends are recorded for 6 calendar years; 2026 shows 3 payments totalling $0.06 a share. The year before, 2025, totalled $0.34 a share.

Across the complete calendar years on file, 2024 returned +9.92% and 2025 returned −50.71%. Of the 4 complete calendar years on file, 1 finished higher. 2026 is still running; the price is +92.95% year to date.

Peer Comparison

Organon & Co. (OGN) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Organon & Co.	OGN	$3.62B	17.7
Eli Lilly and Company	LLY	$1.02T	38.6
Johnson & Johnson	JNJ	$663.28B	32.0
AbbVie Inc.	ABBV	$453.19B	73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Organon & Co. trades at a P/E of 17.7.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

NVS

Novartis AG

$304.10B

AZN

AstraZeneca PLC

$252.33B

View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

AMGN

Amgen Inc.

$236.38B

TMO

Thermo Fisher Scientific Inc.

$226.94B

NVO

Novo Nordisk A/S

$206.02B

ABT

Abbott Laboratories

$187.45B

View all Healthcare stocks →

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Visit website →